THIO, a first-in-class agent, targets telomeres, inducing cancer cell death and activating immune responses in NSCLC. The THIO-101 trial showed a median overall survival of 16.9 months, surpassing ...

As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...

The trial evaluates THIO, a telomere-targeting agent, in combination with Regeneron (NASDAQ:REGN)'s cemiplimab, an immune checkpoint inhibitor, in patients who have not responded to at least two ...

In summary, MAIA Biotechnology’s recent updates regarding its Phase 2 THIO-101 trial demonstrate the company’s commitment to communicating significant developments in its oncology research ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...

Garden Deck Relaxer Chair Metal Zero Gravity Folding Reclining Sun Lounger Bed Detachable Cushion for Patio Beach Black Pink on sale, Amazon Sun Loungers Lunch Break Chair Relaxer Chairs Lazy on sale, ...

The use of chemical hair relaxers has recently been linked to serious illnesses, including uterine and endometrial cancer. If you or a loved one suffered from cancer after using a chemical hair ...